|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011777,
umls-concept:C0013089,
umls-concept:C0026764,
umls-concept:C0039736,
umls-concept:C0042679,
umls-concept:C0087111,
umls-concept:C0205265,
umls-concept:C0332283,
umls-concept:C0392756,
umls-concept:C1511237,
umls-concept:C1550436,
umls-concept:C1555582,
umls-concept:C1705509,
umls-concept:C1831743
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-4
|
|
pubmed:abstractText |
High-dose chemotherapy supported by autologous stem cell transplantation (ASCT) after combined chemotherapy with infusional vincristine/doxorubicin plus dexamethasone is effective in multiple myeloma (MM). Outpatient treatment with bolus vincristine/doxorubicin infusion plus dexamethasone is convenient and has acceptable efficacy and toxicity for MM. Thalidomide has recently been shown to have significant antimyeloma activity. We assessed the efficacy and toxicity of the combination of bolus vincristine/doxorubicin and reduced dose dexamethasone with thalidomide (T-bVAd), administered on an outpatient basis, in untreated MM.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1573-0646
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
175-81
|
|
pubmed:meshHeading |
pubmed-meshheading:19823768-Adult,
pubmed-meshheading:19823768-Antineoplastic Agents,
pubmed-meshheading:19823768-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19823768-Dexamethasone,
pubmed-meshheading:19823768-Disease-Free Survival,
pubmed-meshheading:19823768-Doxorubicin,
pubmed-meshheading:19823768-Female,
pubmed-meshheading:19823768-Humans,
pubmed-meshheading:19823768-Male,
pubmed-meshheading:19823768-Middle Aged,
pubmed-meshheading:19823768-Multiple Myeloma,
pubmed-meshheading:19823768-Stem Cell Transplantation,
pubmed-meshheading:19823768-Thalidomide,
pubmed-meshheading:19823768-Transplantation, Autologous,
pubmed-meshheading:19823768-Treatment Outcome,
pubmed-meshheading:19823768-Vincristine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma.
|
|
pubmed:affiliation |
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article
|
